From basic to translational research and clinical applications, cell culture is an essential technique that underpins the generation of promising cell and gene therapies. Since the quality of cytokines and growth factors can significantly influence the properties and function of cultured cells, these bioactive proteins must be produced to the highest standards… Read More
European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market. Balances for Analytical Purposes aims to ensure quality control of… Read More
Health Canada has approved Moderna’s New Drug Submission (NDS-CV) for Spikevax (elasomeran mRNA vaccine), it has granted full approval (Notice of Compliance or NOC) for Pfizer’s Comirnaty, and it has approved the AstraZeneca vaccine, which will be named Vaxzevria. “Health Canada’s approval of our Covid-19 vaccine is an important milestone as it is our… Read More
The latest sponsored DDW Sitting Down With podcast features Paul Wylie, Director of Multiplex at Abcam looking at enhancing the role of multiplexing in high-throughput screening. Among the topics Lu Rahman will be discussing with Wylie will be the key challenges scientists face with biomarker and… Read More
Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered that loss of ARID1A function enhances a cellular stress response pathway that promotes survival of cancer cells, which become sensitive… Read More
In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his… Read More
Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer. Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the… Read More
This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine. The first article is titled “Precision control of protein release… Read More
An international study led by McMaster University scientists and published in The British Medical Journal show a minority of people living with chronic pain who try medical cannabis may experience important relief and the risk of side effects is typically small. Data from 32 randomised controlled trials showed that… Read More
This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine. The first article is titled “Precision control of protein release… Read More
The last year has seen virology take the forefront of the drug discovery sector as experts collaborated and worked with unprecedented speed to develop a Covid-19 vaccine to reach an end to the global coronavirus pandemic. But other industries have continued to work tirelessly to develop treatments for other… Read More
Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). Liu is Professor of Precision Biomedicine with… Read More
Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had… Read More
The route to market for biosimilars places strong emphasis on characterisation tools for establishing comparability between biosimilar and innovator products. Addressing analytical challenges in fast-forwarding biosimilar development processes requires Implementing sophisticated analytical instruments with advanced technologies. The ICH Q6B, cited by both EMA and FDA, highlights electrophoretic data as… Read More
European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market. Balances for Analytical Purposes aims to ensure quality control of… Read More
A Phase I clinical trial of the world’s first multivariant Covid-19 vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester UK and Manchester University NHS Foundation Trust. Initially involving participants aged 60+, its creators say the drug, GRT-R910, can boost… Read More
